視黃酸受體α

本頁使用了標題或全文手工轉換
維基百科,自由的百科全書
視黃酸受體α
已知的結構
PDB直系同源搜尋: PDBe RCSB
識別號
別名RARA;, NR1B1, RAR, retinoic acid receptor alpha, RARalpha
外部IDOMIM180240 MGI97856 HomoloGene20262 GeneCardsRARA
為以下藥物的標靶
阿達帕林、​alitretinoin、​tamibarotene、​tazarotene、​維A酸[1]
基因位置(人類
17號染色體
染色體17號染色體[2]
17號染色體
視黃酸受體α的基因位置
視黃酸受體α的基因位置
基因座17q21.2起始40,309,180 bp[2]
終止40,357,643 bp[2]
RNA表達模式




查閱更多表達數據
直系同源
物種人類小鼠
Entrez
Ensembl
UniProt
mRNA​序列

​NM_000964
​NM_001024809
​NM_001033603
​NM_001145301
​NM_001145302

NM_001176528
​NM_001177302
​NM_001177303
​NM_009024
​NM_001361954

蛋白序列

NP_001169999
​NP_001170773
​NP_001170774
​NP_033050
​NP_001348883

基因位置​(UCSC)Chr 17: 40.31 – 40.36 MbChr 11: 98.82 – 98.87 Mb
PubMed​查找[4][5]
維基數據
檢視/編輯人類檢視/編輯小鼠

視黃酸受體α(英語:Retinoic acid receptor alphaRAR-α),也稱為NR1B1(核受體第一亞族B組成員1,nuclear receptor subfamily 1, group B, member 1)是一個核受體,在人類基因組中由 RARA 基因編碼。[6][7]

相互作用[編輯]

視黃酸受體α可以與下列蛋白質發生進行交互作用

參考文獻[編輯]

  1. ^ 對retinoic acid receptor alpha起作用的藥物;在維基數據上查看/編輯參考. 
  2. ^ 2.0 2.1 2.2 GRCh38: Ensembl release 89: ENSG00000131759 - Ensembl, May 2017
  3. ^ 3.0 3.1 3.2 GRCm38: Ensembl release 89: ENSMUSG00000037992 - Ensembl, May 2017
  4. ^ Human PubMed Reference:. National Center for Biotechnology Information, U.S. National Library of Medicine. 
  5. ^ Mouse PubMed Reference:. National Center for Biotechnology Information, U.S. National Library of Medicine. 
  6. ^ Identification of a receptor for the morphogen retinoic acid. Nature. 1987, 330 (6149): 624–9. PMID 2825036. doi:10.1038/330624a0. 
  7. ^ High-density genetic map of the BRCA1 region of chromosome 17q12-q21. Genomics. September 1993, 17 (3): 618–23. PMID 8244378. doi:10.1006/geno.1993.1381. 
  8. ^ Liu R, Takayama S, Zheng Y, Froesch B, Chen GQ, Zhang X, Reed JC, Zhang XK. Interaction of BAG-1 with retinoic acid receptor and its inhibition of retinoic acid-induced apoptosis in cancer cells. J. Biol. Chem. July 1998, 273 (27): 16985–92. PMID 9642262. doi:10.1074/jbc.273.27.16985. 
  9. ^ 9.0 9.1 McNamara P, Seo SB, Rudic RD, Sehgal A, Chakravarti D, FitzGerald GA. Regulation of CLOCK and MOP4 by nuclear hormone receptors in the vasculature: a humoral mechanism to reset a peripheral clock. Cell. June 2001, 105 (7): 877–89. PMID 11439184. doi:10.1016/S0092-8674(01)00401-9. 
  10. ^ Despouy G, Bastie JN, Deshaies S, Balitrand N, Mazharian A, Rochette-Egly C, Chomienne C, Delva L. Cyclin D3 is a cofactor of retinoic acid receptors, modulating their activity in the presence of cellular retinoic acid-binding protein II. J. Biol. Chem. February 2003, 278 (8): 6355–62. PMID 12482873. doi:10.1074/jbc.M210697200. 
  11. ^ Lee SK, Jung SY, Kim YS, Na SY, Lee YC, Lee JW. Two distinct nuclear receptor-interaction domains and CREB-binding protein-dependent transactivation function of activating signal cointegrator-2. Mol. Endocrinol. February 2001, 15 (2): 241–54. PMID 11158331. doi:10.1210/me.15.2.241. 
  12. ^ Lee SK, Anzick SL, Choi JE, Bubendorf L, Guan XY, Jung YK, Kallioniemi OP, Kononen J, Trent JM, Azorsa D, Jhun BH, Cheong JH, Lee YC, Meltzer PS, Lee JW. A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivo. J. Biol. Chem. November 1999, 274 (48): 34283–93. PMID 10567404. doi:10.1074/jbc.274.48.34283. 
  13. ^ Ko L, Cardona GR, Chin WW. Thyroid hormone receptor-binding protein, an LXXLL motif-containing protein, functions as a general coactivator. Proc. Natl. Acad. Sci. U.S.A. May 2000, 97 (11): 6212–7. PMC 18584可免費查閱. PMID 10823961. doi:10.1073/pnas.97.11.6212. 
  14. ^ Dowell P, Ishmael JE, Avram D, Peterson VJ, Nevrivy DJ, Leid M. Identification of nuclear receptor corepressor as a peroxisome proliferator-activated receptor alpha interacting protein. J. Biol. Chem. May 1999, 274 (22): 15901–7. PMID 10336495. doi:10.1074/jbc.274.22.15901. 
  15. ^ Guidez F, Ivins S, Zhu J, Söderström M, Waxman S, Zelent A. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood. April 1998, 91 (8): 2634–42. PMID 9531570. 
  16. ^ Dong S, Tweardy DJ. Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways. Blood. April 2002, 99 (8): 2637–46. PMID 11929748. doi:10.1182/blood.V99.8.2637. 
  17. ^ Hong SH, David G, Wong CW, Dejean A, Privalsky ML. SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARalpha) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. August 1997, 94 (17): 9028–33. PMC 23013可免費查閱. PMID 9256429. doi:10.1073/pnas.94.17.9028. 
  18. ^ Hu X, Chen Y, Farooqui M, Thomas MC, Chiang CM, Wei LN. Suppressive effect of receptor-interacting protein 140 on coregulator binding to retinoic acid receptor complexes, histone-modifying enzyme activity, and gene activation. J. Biol. Chem. January 2004, 279 (1): 319–25. PMID 14581481. doi:10.1074/jbc.M307621200. 
  19. ^ Farooqui M, Franco PJ, Thompson J, Kagechika H, Chandraratna RA, Banaszak L, Wei LN. Effects of retinoid ligands on RIP140: molecular interaction with retinoid receptors and biological activity. Biochemistry. February 2003, 42 (4): 971–9. PMID 12549917. doi:10.1021/bi020497k. 
  20. ^ L'Horset F, Dauvois S, Heery DM, Cavaillès V, Parker MG. RIP-140 interacts with multiple nuclear receptors by means of two distinct sites. Mol. Cell. Biol. November 1996, 16 (11): 6029–36. PMC 231605可免費查閱. PMID 8887632. 
  21. ^ Seol W, Choi HS, Moore DD. An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors. Science. May 1996, 272 (5266): 1336–9. PMID 8650544. doi:10.1126/science.272.5266.1336. 
  22. ^ Seol W, Hanstein B, Brown M, Moore DD. Inhibition of estrogen receptor action by the orphan receptor SHP (short heterodimer partner). Mol. Endocrinol. October 1998, 12 (10): 1551–7. PMID 9773978. doi:10.1210/me.12.10.1551. 
  23. ^ Perlmann T, Jansson L. A novel pathway for vitamin A signaling mediated by RXR heterodimerization with NGFI-B and NURR1. Genes Dev. April 1995, 9 (7): 769–82. PMID 7705655. doi:10.1101/gad.9.7.769. 
  24. ^ Zhong S, Delva L, Rachez C, Cenciarelli C, Gandini D, Zhang H, Kalantry S, Freedman LP, Pandolfi PP. A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins. Nat. Genet. November 1999, 23 (3): 287–95. PMID 10610177. doi:10.1038/15463. 
  25. ^ Benkoussa M, Brand C, Delmotte MH, Formstecher P, Lefebvre P. Retinoic acid receptors inhibit AP1 activation by regulating extracellular signal-regulated kinase and CBP recruitment to an AP1-responsive promoter. Mol. Cell. Biol. July 2002, 22 (13): 4522–34. PMC 133906可免費查閱. PMID 12052862. doi:10.1128/MCB.22.13.4522-4534.2002. 
  26. ^ Bugge TH, Pohl J, Lonnoy O, Stunnenberg HG. RXR alpha, a promiscuous partner of retinoic acid and thyroid hormone receptors. EMBO J. April 1992, 11 (4): 1409–18. PMC 556590可免費查閱. PMID 1314167. 
  27. ^ Kim HJ, Yi JY, Sung HS, Moore DD, Jhun BH, Lee YC, Lee JW. Activating signal cointegrator 1, a novel transcription coactivator of nuclear receptors, and its cytosolic localization under conditions of serum deprivation. Mol. Cell. Biol. September 1999, 19 (9): 6323–32. PMC 84603可免費查閱. PMID 10454579. doi:10.1128/mcb.19.9.6323. 
  28. ^ He B, Wilson EM. Electrostatic modulation in steroid receptor recruitment of LXXLL and FXXLF motifs. Mol. Cell. Biol. March 2003, 23 (6): 2135–50. PMC 149467可免費查閱. PMID 12612084. doi:10.1128/MCB.23.6.2135-2150.2003. 
  29. ^ Zeng M, Kumar A, Meng G, Gao Q, Dimri G, Wazer D, Band H, Band V. Human papilloma virus 16 E6 oncoprotein inhibits retinoic X receptor-mediated transactivation by targeting human ADA3 coactivator. J. Biol. Chem. November 2002, 277 (47): 45611–8. PMID 12235159. doi:10.1074/jbc.M208447200. 
  30. ^ Martin PJ, Delmotte MH, Formstecher P, Lefebvre P. PLZF is a negative regulator of retinoic acid receptor transcriptional activity. Nucl. Recept. September 2003, 1 (1): 6. PMC 212040可免費查閱. PMID 14521715. doi:10.1186/1478-1336-1-6. 

延伸閱讀[編輯]